Top Markets
Coin of the day
BriaCell Therapeutics Corp. BriaCell Therapeutics Corp.

BriaCell Therapeutics Corp.

BCTX
Rank in Stocks #18288
BriaCell Therapeutics Corp., an immuno-oncology biotechnology company, engages... BriaCell Therapeutics Corp., an immuno-oncology biotechnology company, engages in developing immunotherapies for the treatment of cancer. Its lead candidate is Bria-IMT that is in Phase I/IIa clinical trial in a combination study with immune checkpoint inhibitors for the treatment of breast cancer. The company also has a cooperative research and development agreement with the National Cancer Institute for developing Bria-OTS, a personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test. BriaCell Therapeutics Corp. is headquartered in West Vancouver, Canada.
Share Price
$4.32
Market Cap
$8.14M
Change (1 day)
-6.49%
Change (1 year)
-2.88%
Country
CA
Trade BriaCell Therapeutics Corp. (BCTX)

Category

P/S ratio for BriaCell Therapeutics Corp. (BCTX)
P/S ratio as of 2026 TTM: 0
According to BriaCell Therapeutics Corp. latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 0. At the end of 2026 the company had a P/S ratio of 0.
P/S ratio history for BriaCell Therapeutics Corp. from 2026 to 2026
P/S ratio at the end of each year
Year P/S Ratio Change
Not enough data for the provided dates.
P/S ratio for similar companies or competitors
Company P/S Ratio P/S Ratio Difference Country
3.54 -
DK
9.38 -
US
5.47 -
US
6.65 -
BE
15.23 -
NL